MSC2015103B

MSC2015103B (also known as AS703988) is an oral, highly-selective small molecule allosteric inhibitor of MEK1 and MEK2, key enzymes in the MAPK signaling pathway. By selectively binding to and inhibiting the activity of MEK1/2, it prevents activation of downstream effector proteins and transcription factors, which may result in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. Dysregulation of the MAPK pathway is implicated in many cancers. The drug was initially developed by Merck KGaA (Darmstadt, Germany) and has been licensed to Day One Biopharmaceuticals for further development[1][3][5][6].